Daniel Barenboim, Parkinson's disease
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
Dancing the Blues Away' Seen in Brain Imaging in People With Parkinson's Disease, New Study Finds Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the ...
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback